Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer

Yanjun Ge,1,* Yuchen Zhang,1,* Kong-Nan Zhao,2,3 Haiyan Zhu1,2 1Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2School of Basic Medical Science, Wenzhou Medical University, Wenzhou, P...

Full description

Bibliographic Details
Main Authors: Ge Y, Zhang Y, Zhao KN, Zhu H
Format: Article
Language:English
Published: Dove Medical Press 2022-09-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/emerging-therapeutic-strategies-of-different-immunotherapy-approaches--peer-reviewed-fulltext-article-DDDT
_version_ 1811262124755779584
author Ge Y
Zhang Y
Zhao KN
Zhu H
author_facet Ge Y
Zhang Y
Zhao KN
Zhu H
author_sort Ge Y
collection DOAJ
description Yanjun Ge,1,* Yuchen Zhang,1,* Kong-Nan Zhao,2,3 Haiyan Zhu1,2 1Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2School of Basic Medical Science, Wenzhou Medical University, Wenzhou, People’s Republic of China; 3Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia*These authors contributed equally to this workCorrespondence: Haiyan Zhu, Shanghai First Maternity and Infant Hospital, No. 2699 Gaokexi Road, Shanghai, 200092, People’s Republic of China, Tel +86 13758465255, Email zhuhaiyandoc@sina.comAbstract: Currently, therapeutic methods for advanced and recurrent cervical cancer patients are limited and unsatisfactory. Immunotherapy is a promising approach for cancer treatment. However, its investigation and application in cervical cancer remain slow. Although pembrolizumab is a remarkable milestone as the first anti-PD-1 mAb approved by the FDA for treating cervical cancer, it shows relatively low response rate. It is noticed that multiple novel immune checkpoints have emerged in recent years, such as CTLA-4, TIGIT, LAG-3, TIM-3, and A2AR. Accumulated studies have suggested that strategies combining the PD-1/PD-L1 inhibitors and different immunotherapies or biotherapies could enhance the antitumor efficacy in human cancers. In this review article, we provide an overview of anti-PD-1/PD-L1-based immunotherapy in cervical cancer treatment. We further summarize the developmental strategies of different immunotherapies or biotherapies combined with PD-1/PD-L1 blockade for treating cervical cancer. We also discuss how these new combined therapies increase the therapeutic benefit gained from experimental evidence in cervical cancer.Keywords: cervical cancer, immunotherapy, PD-1/PD-L1, combinatorial strategy, mechanism, clinical practice
first_indexed 2024-04-12T19:18:23Z
format Article
id doaj.art-a136cfe129e24a7e81621af57dde1916
institution Directory Open Access Journal
issn 1177-8881
language English
last_indexed 2024-04-12T19:18:23Z
publishDate 2022-09-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj.art-a136cfe129e24a7e81621af57dde19162022-12-22T03:19:39ZengDove Medical PressDrug Design, Development and Therapy1177-88812022-09-01Volume 163055307078094Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical CancerGe YZhang YZhao KNZhu HYanjun Ge,1,* Yuchen Zhang,1,* Kong-Nan Zhao,2,3 Haiyan Zhu1,2 1Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2School of Basic Medical Science, Wenzhou Medical University, Wenzhou, People’s Republic of China; 3Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia*These authors contributed equally to this workCorrespondence: Haiyan Zhu, Shanghai First Maternity and Infant Hospital, No. 2699 Gaokexi Road, Shanghai, 200092, People’s Republic of China, Tel +86 13758465255, Email zhuhaiyandoc@sina.comAbstract: Currently, therapeutic methods for advanced and recurrent cervical cancer patients are limited and unsatisfactory. Immunotherapy is a promising approach for cancer treatment. However, its investigation and application in cervical cancer remain slow. Although pembrolizumab is a remarkable milestone as the first anti-PD-1 mAb approved by the FDA for treating cervical cancer, it shows relatively low response rate. It is noticed that multiple novel immune checkpoints have emerged in recent years, such as CTLA-4, TIGIT, LAG-3, TIM-3, and A2AR. Accumulated studies have suggested that strategies combining the PD-1/PD-L1 inhibitors and different immunotherapies or biotherapies could enhance the antitumor efficacy in human cancers. In this review article, we provide an overview of anti-PD-1/PD-L1-based immunotherapy in cervical cancer treatment. We further summarize the developmental strategies of different immunotherapies or biotherapies combined with PD-1/PD-L1 blockade for treating cervical cancer. We also discuss how these new combined therapies increase the therapeutic benefit gained from experimental evidence in cervical cancer.Keywords: cervical cancer, immunotherapy, PD-1/PD-L1, combinatorial strategy, mechanism, clinical practicehttps://www.dovepress.com/emerging-therapeutic-strategies-of-different-immunotherapy-approaches--peer-reviewed-fulltext-article-DDDTcervical cancerimmunotherapypd-1/pd-l1combinatorial strategymechanismclinical practice
spellingShingle Ge Y
Zhang Y
Zhao KN
Zhu H
Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
Drug Design, Development and Therapy
cervical cancer
immunotherapy
pd-1/pd-l1
combinatorial strategy
mechanism
clinical practice
title Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
title_full Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
title_fullStr Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
title_full_unstemmed Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
title_short Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
title_sort emerging therapeutic strategies of different immunotherapy approaches combined with pd 1 pd l1 blockade in cervical cancer
topic cervical cancer
immunotherapy
pd-1/pd-l1
combinatorial strategy
mechanism
clinical practice
url https://www.dovepress.com/emerging-therapeutic-strategies-of-different-immunotherapy-approaches--peer-reviewed-fulltext-article-DDDT
work_keys_str_mv AT gey emergingtherapeuticstrategiesofdifferentimmunotherapyapproachescombinedwithpd1pdl1blockadeincervicalcancer
AT zhangy emergingtherapeuticstrategiesofdifferentimmunotherapyapproachescombinedwithpd1pdl1blockadeincervicalcancer
AT zhaokn emergingtherapeuticstrategiesofdifferentimmunotherapyapproachescombinedwithpd1pdl1blockadeincervicalcancer
AT zhuh emergingtherapeuticstrategiesofdifferentimmunotherapyapproachescombinedwithpd1pdl1blockadeincervicalcancer